SCHEMBL17479797

SCHEMBL17479797

CN(C1CCCCC1)S(=O)(=O)c1cccc(-c2nc3ccccc3o2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.53
▸ KMT2A Q03164 4/20 0.53
▸ ALDH1A1 P00352 3/20 0.53
▸ KDM4E B2RXH2 3/20 0.53
▸ MCOLN3 Q8TDD5 1/20 0.50
▸ MAPT P10636 4/20 0.47
▸ HPGD P15428 3/20 0.46
▸ LMNA P02545 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ RCE1 Q9Y256 1/20 0.46
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ PTPN2 P17706 6/20 0.44
▸ PTPN1 P18031 6/20 0.44
▸ PTPN5 P54829 6/20 0.44
▸ TSHR P16473 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17479705 0.81 HSD17B10 (0.42) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL16459106 0.74 UTRN (0.64) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL17479807 0.74 ALDH1A1 (0.60) MEN1KMT2AALDH1A1KDM4EMCOLN3
SCHEMBL9595305 0.74 NPC1 (0.57) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL17479791 0.74 KDM4E (0.42) ALDH1A1KDM4EMAPTHPGDLMNA
SCHEMBL17479698 0.72 SMN1; SMN2 (0.44) KMT2AALDH1A1KDM4EMAPTHPGD
SCHEMBL5510992 0.72 ALDH1A1 (0.55) MEN1KMT2AALDH1A1KDM4EMCOLN3
SCHEMBL4159760 0.72 ALDH1A1 (1.00) MEN1KMT2AALDH1A1KDM4EMCOLN3
SCHEMBL12076741 0.71 ALDH1A1 (0.62) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL17479006 0.71 SMN1; SMN2 (0.43) KMT2AALDH1A1KDM4EMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3174859-B1 FLT3 RECEPTOR ANTAGONISTS INST NAT SANTE RECH MED (FR) 2020-04-29 — — EP claimed
US-10065937-B2 FLT3 receptor antagonists INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2018-09-04 — — US claimed
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2017-08-17 — — US claimed
EP-3174859-A1 FLT3 RECEPTOR ANTAGONISTS INSERM - Institut National de la Santé et de la Recherche Médicale (FR) 2017-06-07 — — EP claimed
WO-2016016370-A1 FLT3 RECEPTOR ANTAGONISTS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-02-04 — — WO claimed
CN-107001283-B FLT3 receptor antagonists 国家健康与医学研究院 2021-05-25 — — CN disclosed
US-20200171022-A1 FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-06-04 — — US disclosed
CN-111093640-A FLT3 inhibitors for improving opioid pain therapy 国家健康与医学研究院 2020-05-01 — — CN disclosed
EP-3174859-B1 FLT3 RECEPTOR ANTAGONISTS INST NAT SANTE RECH MED (FR) 2020-04-29 — — EP disclosed
EP-3624780-A1 FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2020-03-25 — — EP disclosed
WO-2018211018-A1 FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2018-11-22 — — WO disclosed
US-10065937-B2 FLT3 receptor antagonists INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2018-09-04 — — US disclosed
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2017-08-17 — — US disclosed
EP-3174859-A1 FLT3 RECEPTOR ANTAGONISTS INSERM - Institut National de la Santé et de la Recherche Médicale (FR) 2017-06-07 — — EP disclosed
WO-2016016370-A1 FLT3 RECEPTOR ANTAGONISTS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS FLT3, CSF1R, CSF3R MEN1 1656/4885KMT2A 1531/4885ALDH1A1 2419/4885
US-10065937-B2 FLT3 receptor antagonists FLT3, CSF1R, CSF3R MEN1 1656/4885KMT2A 1531/4885ALDH1A1 2419/4885
US-20200171022-A1 FLT3 INHIBITORS FOR IMPROVING PAIN TREATMENTS BY OPIOIDS FLT3, CSF1R, OPRL1 MEN1 4532/4885KMT2A 426/4885ALDH1A1 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback